CI

At a glance

ClinicalIndex Comparison Record
Phase 4Active· 17 enrolled
Drug / intervention
Dupilumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03935971
NCT03935971Phase 4Active
CompareCT.gov

The Effects of Dupilumab on Allergic Contact Dermatitis

Brigham and Women's Hospital·interventional·Posted May 2, 2019·Updated Feb 27, 2026

In Brief

A Phase 4 clinical trial evaluating Dupilumab for Allergic Contact Dermatitis. Active but no longer recruiting, targeting 17 participants across 1 site.

Detailed Summary

The aim of this study is to investigate the effects of dupilumab on allergic contact dermatitis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAllergic Contact Dermatitis
CountriesUnited States
CollaboratorsRegeneron Pharmaceuticals

Timeline

Phase 4Active
2020202120222023202420252026
First PostedMay 2, 2019
Enrollment StartDec 18, 2019
Primary CompletionDec 31, 2024
Study CompletionJul 31, 2026
TodayJul 2, 2026
Enrollment to primary: 5.0 yearsPosted 7.2 years ago

Interventions

Dupilumabdrug

See arm/group description